Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers’ DNA data
Monday, 19 May 2025 ()
Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers’ DNA data. Through the deal, Regeneron aims to bolster its capabilities in genomics-driven drug discovery…
|
||||
|
|
||||
You Might Like |
||||
